Neurokinin Receptor Antagonists Easing Menopausal Sleep Disruptions
Neurokinin receptor antagonists significantly improve sleep disturbances in menopausal women experiencing moderate-to-severe vasomotor symptoms, according to a meta-analysis published in Menopause and presented at the Menopause Society annual meeting. The drugs demonstrated measurable improvements as early as 4 weeks, with a standardized mean difference of -3.94 compared with placebo, reported Maria Julia Lemos, MD, of Kurah Women’s Health Institute in Macaé, Brazil, and colleagues.
Seven trials show sleep benefits for women
The systematic review and meta-analysis analyzed data from seven placebo-controlled trials published up to May 2026, encompassing 3,184 women with a mean age of 54.5. Researchers evaluated 949 participants taking fezolinetant, 864 taking elinzanetant, and 1,371 receiving placebo. Five of the trials utilized the Patient-Reported Outcomes Measurement Information System Sleep Disturbance-Short Form 8b questionnaire to measure sleep quality, restfulness, and difficulty falling and staying asleep.
The sleep benefits persisted at 12 weeks with a standardized mean difference of -3.11 and at 24 weeks with a standardized mean difference of -2.04. JoAnn E. Manson, MD, MPH, DrPH, of Harvard Medical School and past president of the Menopause Society, noted that the research fills an important knowledge gap regarding non-hormonal treatments for vasomotor symptoms. Manson was not involved in the study.
Elinzanetant shows greater early effect than fezolinetant
Both evaluated non-hormonal medications target the brain’s thermoregulation center to alleviate hot flashes and associated sleep disruptions. Fezolinetant acts as an NK3 receptor antagonist, while elinzanetant functions as a dual NK1/NK3 receptor antagonist. Subgroup analyses indicated that both drugs significantly improved sleep through 12 weeks, though elinzanetant showed a greater magnitude of effect at 4 weeks with a standardized mean difference of -5.24 compared with -1.98 for fezolinetant.
Frequently Asked Questions About Menopausal Sleep Treatments
Why are neurokinin receptor antagonists considered an alternative to hormone therapy?
While menopausal hormone therapy remains the preferred treatment for vasomotor symptoms, some women have medical contraindications or prefer non-hormonal options. These targeted agents offer relief for hot flashes and sleep disturbances without utilizing hormones.
What specific sleep metrics did the meta-analysis track?
Five of the included trials used the PROMIS SD-SF-8b questionnaire to evaluate sleep quality, restfulness, and the specific difficulty of falling and staying asleep over a 7-day period.
What limitations did the researchers identify in the analysis?
Lemos noted that the review included relatively few trials, relied on patient-reported sleep outcomes, and involved high heterogeneity among patient populations, regimens, and follow-up schedules.
Worth a look